COT-14 OUTCOMES OF MEDULLOBLASTOMA IN KOBE CHILDREN, S HOSPITAL OVER THE RECENT 11 YEARS. (3rd December 2022)

• Record Type: Journal Article
• Authors: Kawamura, Atsufumi; Koyama, Junji; Akutsu, Nobuyuki; Enami, Haryka; Hayashi, Hideya
• Is Part Of: Neuro-oncology advances. Volume 4(2022)Supplement 3
• Page Start: iii25
• Page End: iii26
• Publication Date: 2022-12-03
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdac167.101
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Introduction: Medulloblastoma is the most frequent malignant brain tumor in children, which 5-year survival rate have improved to 70-85%. In this study, we retrospectively reviewed outcomes and late complications of 31 medulloblastoma cases treated at our institute from 2010 to 2021. Cases: The mean age of the cases was 6.5 years. 22 cases were total resection and 17 were judged to be in the high-risk group. With respect to histopathological diagnosis, 23 cases were classified as Classic type, 2 as Desmoplastic/nodular type, 2 as With extensive nodularity type, and 4 as Anaplastic/Large cell type. As for molecular analysis, WNT was 2, SHH was 3, Group 3 was 3, Group 4 was 8 cases. One case was lost due to relocation. Results: 21 patients have no recurrence of medulloblastoma, but two were victims of second cancers. The remaining 19 cases were all in the standard-risk group and survived with a complete reaction (CR). There were 9 cases of recurrence (including disseminated disease) and the survived case after retreatment was only one in the high-risk group which indicated CR. Discussion: The 5-year survival rate for patients in standard-risk group at our institution was 92.3%, indicating improved outcomes. The poor prognosis group could be divided in group who developed recurrence or second cancers after 5 years or more and group who indicated insufficient reaction to multimodality treatment and died around 2 years after diagnosis. As late complications, there were 5 cases of higher functional impairment, who were 16.7% of whole cases and almost in the high-risk group. It is necessary to pursue further treatment for the high-risk group and to recognize that the number of survivors of medulloblastoma cases is increasing, and to support for the AYA generation.